Chang et al. found that rosuvastatin alleviates experimental HPS through blockade of pulmonary inflammatory angiogenesis via downregulation of the TNF-α/NF-κB and VEGF/Rho-associated A kinase pathways10. This evidence concerns the gene NFKB1 and Hermansky-Pudlak syndrome.